nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

09.01.2024 | Original Article

Medication-related osteonecrosis of the lower jaw without osteolysis on computed tomography images

verfasst von: Yuka Kojima, Shunsuke Sawada, Yuki Sakamoto

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Surgery is the standard treatment for medication-related osteonecrosis of the jaw (MRONJ). This study reviewed patients with mandibular MRONJ who underwent surgical treatment, and in particular the characteristics of non-osteolytic MRONJ with no evidence of osteolysis on CT were described.

Materials and methods

We conducted a retrospective study of patients with mandibular MRONJ who underwent surgery between January 2016 and September 2022. Various clinical and imaging factors regarding treatment outcomes were investigated and analyzed. Additionally, the disease course of non-osteolytic MRONJ was examined in detail.

Results

This study included 55 patients (66 surgeries) with a mean age of 74.7. The primary disease was osteoporosis (24 patients) and malignancy (31 patients); the type of antiresorptive agent was bisphosphonate (BP) in 21 patients and denosumab (DMB) in 26. BP was initially administered; however, it was changed to DMB in eight patients. Preoperatively, the cumulative cure rates for all 66 surgeries were 72.8% at 1 year and 77.3% at 2 years. Cure rates were significantly lower in patients with malignancy, those without osteolysis, and those who underwent sequestrum removal or marginal mandibulectomy than those with osteoporosis, osteolysis, and segmental mandibulectomy. Non-osteolytic MRONJ was observed in eight patients, all with malignancy and receiving high-dose DMB. Only two patients were cured after the initial surgery, and most patients ultimately underwent segmental mandibulectomy.

Conclusions

Surgical treatment yielded good treatment outcomes in most patients with mandibular MRONJ; however, the cure rate was lower in patients with malignancy who showed no osteolysis on CT images.

Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg Am Assoc Oral Maxillofac Surg 72:1938–1956. https://doi.org/10.1016/j.joms.2014.04.031CrossRef

Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 37:2270–2290. https://doi.org/10.1200/JCO.19.01186CrossRefPubMed

Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S (2017) Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 35:6–19. https://doi.org/10.1007/s00774-016-0810-7CrossRef

Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, Shibuya Y, Ueda N, Kirita T, Nakahara H, Shinohara M, Umeda M (2017) Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res 32:2022–2029. https://doi.org/10.1002/jbmr.3191CrossRefPubMed

Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta GM, Gennai S, Goia F, Miccoli M, Peluso F, Scoletta M, Solazzo L, Colella G (2012) Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases. J Oral Maxillofac Surg 70:2501–2507. https://doi.org/10.1016/j.joms.2012.05.019CrossRefPubMed

Ruggiero SL, Kohn N (2015) Disease stage and mode of therapy are important determinants of treatment outcomes for medication related osteonecrosis of the jaw. J Oral Maxillofac Surg 73:S94–S100. https://doi.org/10.1016/j.joms.2015.09.024CrossRefPubMed

Kim HY, Lee SJ, Kim SM, Myoung H, Hwang SJ, Choi JY, Lee JH, Choung PH, Kim MJ, Seo BM (2017) Extensive surgical procedures result in better treatment outcomes for bisphosphonate-related osteonecrosis of the jaw in patients with osteoporosis. J Oral Maxillofac Surg 75:1404–1413. https://doi.org/10.1016/j.joms.2016.12.014CrossRefPubMed

Mücke T, Koschinski J, Deppe H, Wagenpfeil S, Pautke C, Mitchell DA, Wolff KD, Hölzle F (2011) Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws. J Cancer Res Clin Oncol 137:907–913. https://doi.org/10.1007/s00432-010-0953-1CrossRefPubMed

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg 80:920–943. https://doi.org/10.1016/j.joms.2022.02.008CrossRefPubMed

10.

Suei Y (2013) Radiographic findings of bisphosphonate-related osteomyelitis of the jaw: investigation of the diagnostic points by comparison with radiation osteomyelitis, suppurative osteomyelitis, and diffuse sclerosing osteomyelitis. Oral Radiol 29:121–134CrossRef

11.

Kojima Y, Kawaoka Y, Sawada S, Hayashida S, Okuyama K, Yutori H, Kawakita A, Ishida S, Soutome S, Yanamoto S, Umeda M, Iwai H (2019) Clinical significance of periosteal reaction as a predictive factor for treatment outcome of medication-related osteonecrosis of the jaw. J Bone Miner Metab 37:913–919. https://doi.org/10.1007/s00774-019-00994-1CrossRefPubMed

12.

Kojima Y, Soutome S, Otsuru M, Hayashida S, Sakamoto Y, Sawada S, Umeda M (2022) Factors exacerbating clinical symptoms and CT findings in patients with medication-related osteonecrosis of the jaw receiving conservative therapy: a multicenter retrospective study of 53 cases. Int J Environ Res Public Health 19:7854. https://doi.org/10.3390/ijerph19137854CrossRefPubMedPubMedCentral

13.

Soutome S, Yanamoto S, Sumi M, Hayashida S, Kojima Y, Sawada S, Rokutanda S, Iwai H, Saito T, Umeda M (2021) Effect of periosteal reaction in medication-related osteonecrosis of the jaw on treatment outcome after surgery. J Bone Miner Metab 39:302–310. https://doi.org/10.1007/s00774-020-01154-6CrossRefPubMed

14.

Soutome S, Otsuru M, Hayashida S, Yanamoto S, Sasaki M, Takagi Y, Sumi M, Kojima Y, Sawada S, Iwai H, Umeda M, Saito T (2021) Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy. Support Care Cancer 29:6361–6368. https://doi.org/10.1007/s00520-021-06214-9CrossRefPubMed

15.

Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, Di Lenarda R, Biasotto M (2014) A systematic review of therapeutical approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral Oncol 50:1049–1057. https://doi.org/10.1016/j.oraloncology.2014.08.016CrossRefPubMed

16.

Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S (2015) Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 44:568–585. https://doi.org/10.1016/j.ijom.2015.01.026CrossRefPubMed

17.

Bisdas S, Chambron Pinho N, Smolarz A, Sader R, Vogl TJ, Mack MG (2008) Bisphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 patients. Clin Radiol 63:71–77. https://doi.org/10.1016/j.crad.2007.04.023CrossRefPubMed

18.

Wongratwanich P, Shimabukuro K, Konishi M, Nagasaki T, Ohtsuka M, Suei Y, Nakamoto T, Verdonschot RG, Kanesaki T, Sutthiprapaporn P, Kakimoto N (2021) Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review. Dentomaxillofac Radiol 50:20200417. https://doi.org/10.1259/dmfr.20200417CrossRefPubMedPubMedCentral

19.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092. https://doi.org/10.1016/j.ejca.2012.08.002CrossRefPubMed

20.

Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62. https://doi.org/10.1056/NEJMoa0802633CrossRefPubMedPubMedCentral

21.

Kopper L (2012) Denosumab–a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts. Pathol Oncol Res 18:743–747. https://doi.org/10.1007/s12253-012-9538-4CrossRefPubMed

22.

Baba A, Ojiri H, Goto TK, Ikeda K, Yamauchi H, Ogino N, Mogami T (2019) CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication), Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4). Jpn Dent Sci Rev 55:58–64CrossRefPubMedPubMedCentral

23.

Moridera K, Kitajima K, Yoshikawa K, Takaoka K, Tsuchitani T, Noguchi K, Kishimoto H, Yamakado K (2022) Usefulness of quantitative bone SPECT/CT for medication-related osteonecrosis of the jaw in clinical settings. Jpn J Radiol 40:492–499. https://doi.org/10.1007/s11604-021-01226-1CrossRefPubMed

24.

Soutome S, Otsuru M, Hayashida S, Murata M, Yanamoto S, Sawada S, Kojima Y, Funahara M, Iwai H, Umeda M, Saito T (2021) Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients. Sci Rep 11:17226. https://doi.org/10.1038/s41598-021-96480-8ADSCrossRefPubMedPubMedCentral

25.

Soutome S, Otsuru M, Murata M, Morishita K, Omori K, Suyama K, Hayashida S, Umeda M, Saito T (2022) Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study. Support Care Cancer 30:7241–7248. https://doi.org/10.1007/s00520-022-07134-yCrossRefPubMed

Titel: Medication-related osteonecrosis of the lower jaw without osteolysis on computed tomography images
verfasst von: Yuka Kojima
Shunsuke Sawada
Yuki Sakamoto
Publikationsdatum: 09.01.2024
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 1/2024
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-023-01484-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study

Body mass index, height, and osteoporotic fracture risk in community-dwelling Japanese people aged 40–74 years

Hypergravity stimulates mechanical behavior and micro-architecture of tibia in rats

Causal relationship between glycemic traits and bone mineral density in different age groups and skeletal sites: a Mendelian randomization analysis

Safety and effectiveness of risedronate in Paget’s disease of bone: postmarketing surveillance study in Japan

Tea consumption and risk of bone health: an updated systematic review and meta-analysis